<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104176">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01879761</url>
  </required_header>
  <id_info>
    <org_study_id>13-0491</org_study_id>
    <nct_id>NCT01879761</nct_id>
  </id_info>
  <brief_title>Immune Resolution After Staphylococcus Aureus Bacteremia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: University of Chicago IRB</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how monocyte HLA-DR and other markers of immune
      function change with time in patients with and without prior immune dysfunction who survive
      sepsis from Staphylococcus aureus bacteremia.

      We hypothesize that patients with prior immune dysfunction will have greater reductions in
      HLA-DR and other markers of immune function after an episode of sepsis than people who do
      not have prior immune dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>HLA-DR and cytokines</measure>
    <time_frame>0-30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent expression of HLA-DR on monocytes will be measured by flow cytometry. Cytokine levels will be measured by ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Infections</measure>
    <time_frame>0-90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>0-90 days</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Immune Response To Sepsis</condition>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Immunosuppressed</arm_group_label>
    <description>Immunosuppressed includes patients with any one of the following:
a diagnosis of a hematological malignancy
a diagnosis of HIV
myelosuppressive chemotherapy in the previous 90 days
immune-modulating medications in the previous 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Immunosuppressed</arm_group_label>
    <description>Subject does not fit immunosuppressed criteria</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Isolated monocytes from whole blood for HLA-DR measurement. Serum and plasma for cytokine
      measurements
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital inpatients with Staphylococcus aureus bacteremia who are over 18 years old.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one blood culture positive for S. aureus

          -  Patients aged ≥18 years

          -  At least two of four systemic inflammatory response syndrome (SIRS) criteria on the
             day of positive blood cultures. SIRS criteria are:

               -  Body temperature less than 36°C(96.8°F) or greater than 38°C(100.4°F)

               -  Heart rate greater than 90 beats per minute

               -  Tachypnea (high respiratory rate), with greater than 20 breaths per minute; or,
                  an arterial partial pressure of carbon dioxide less than 32 mmHg

               -  WBC less than 4000 cells/mm³ (4 x 109 cells/L) or greater than 12,000 cells/mm³
                  (12 x 109 cells/L); or the presence of greater than 10% immature neutrophils
                  (band forms)

        Exclusion Criteria:

          -  Sequential Organ Failure Assessment (SOFA) score &gt; 12 on day of positive blood
             cultures

          -  Survival expected to be &lt; 7 days from positive blood cultures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Greenberg, MD</last_name>
      <phone>773-702-1000</phone>
      <email>jared.greenberg@uchospitals.edu</email>
    </contact>
    <contact_backup>
      <last_name>John Kress, MD</last_name>
      <phone>773-702-1000</phone>
      <email>jkress@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jared A Greenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John P Kress, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne I Sperling, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert S Daum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Z David, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhakti K Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne S Pohlman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>June 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppressed</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>HLA-DR</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
